Q2 2018 13F Holders as of 30 Jun 2018
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
166M
-
Number of holders
-
139
-
Total 13F shares, excl. options
-
32.3M
-
Shares change
-
+3.11M
-
Total reported value, excl. options
-
$739M
-
Value change
-
+$66M
-
Put/Call ratio
-
0.1
-
Number of buys
-
85
-
Number of sells
-
-62
-
Price
-
$22.86
Significant Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) as of Q2 2018
164 filings reported holding CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share as of Q2 2018.
CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) has 139 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 32.3M shares
of 166M outstanding shares and own 19.52% of the company stock.
Largest 10 shareholders include FMR LLC (5.84M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.25M shares), BlackRock Inc. (3.23M shares), VANGUARD GROUP INC (2.12M shares), PERCEPTIVE ADVISORS LLC (1.92M shares), STATE STREET CORP (1.71M shares), RENAISSANCE TECHNOLOGIES LLC (1.41M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (730K shares), Aquilo Capital Management, LLC (650K shares), and FIL Ltd (560K shares).
This table shows the top 139 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.